Anti-inflammatory drugs protect against Alzheimer disease at low doses

Archives of Neurology

Volumn 57, Issue 11, 2000, Pages 1586-1591

  Broe, G Anthony ^a,b,c   Grayson, David A ^a,b   Creasey, Helen M ^a,b   Waite, Louise M ^a,b   Casey, Barney J ^a,b   Bennett, Hayley P ^a,b   Brooks, William S ^a,b   Halliday, Glenda M ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPHYLLINE; ANTACID AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIGLAUCOMA AGENT; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LAXATIVE; METHYLDOPA; NEUROLEPTIC AGENT; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; SEDATIVE AGENT; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VASODILATOR AGENT;

AGED; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DEMENTIA; DOSE RESPONSE; DRUG EFFECT; DRUG USE; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0033751840     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.11.1586     Document Type: Article

References (28)

1. Brain aging and neurodegenerative diseases: A major public health issue for the twenty-first century
2. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
3. A double-blind placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
4. Clinical trial of indomethacin in Alzheimer's disease
5. Nonsteriodal anti-inflammatory drugs in Alzheimer's disease
6. Risk of Alzheimer's disease and duration of NSAID use
7. Do antiarthritic drugs decrease the risk for cognitive decline?
8. Aspirin, anti-inflammatory drugs and risk of dementia
9. The importance of inflammatory mechanisms in Alzheimers disease
10. Rheumatoid arthritis and senile dementia of the Alzheimer type
11. Anti-inflammatory drugs and Alzheimer's disease
12. Prevalence of dementia amongst elderly Japanese with leprosy: Apparent effect of chronic drug therapy
13. Nonsteroidal anti-inflammatory drugs and cognitive function: Do they have a beneficial or deleterious effect?
14. APOE genotype predicts when - Not whether - One is predisposed to develop Alzheimer's disease
15. The prevalence of apoE-ε4 in Alzhimer's disease is age dependent
16. Neurological signs, aging and the neurodegenerative syndromes
17. Neurodegenerative and other chronic disorders among people aged 75 years and over in the community
18. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
19. The Canadian Study of Health and Aging; Risk factors for Alzheimer's disease in Canada
20. Nonsteroidal anti-inflammatory drugs and cognitive decline in the elderly
21. Building a better aspirin
22. Analgesics - Antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout
23. Platelets are the primary source of amyloid β-peptide in human blood
24. The amyloid precursor protein of Alzheimer's disease is released by human platelets
25. A radical vascular connection
26. β-Amyloid-mediated vasoactivity and vascular endothelial damage
27. Cerebrovascular endothelial dysfunction mediated by β-amyloid